Affiliation:
1. Network Aging Research, Heidelberg University, Heidelberg, Germany
2. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
Abstract
Background: Attitudes, motivations, and barriers to pre-symptomatic screening for Alzheimer’s disease (AD) in the general population are unclear, and validated measurement tools are lacking. Objective: Translation and validation of the German version of the “Perceptions regarding pRE-symptomatic Alzheimer’s Disease Screening” (PRE-ADS) questionnaire. Methods: A convenience sample (N = 256) was recruited via an online platform. Validation of the PRE-ADS-D consisted of assessments of reliability, structural validity using Principal Component Analysis (PCA) and Exploratory Factor Analysis (EFA) and construct validity using known-group tests. A subscale “Acceptability of Screening”, with 5 PRE-ADS-D items, was extracted to measure acceptance of screening in clinical practice. The STROBE checklist was used for reporting. Results: EFA revealed a three-factor model for the PRE-ADS-D. Acceptable to good internal consistency was found for the 25-item scale (α= 0.78), as well as for the three factors “Concerns about Screening” (α= 0.85), “Intention to be Screened” (α= 0.87), and “Preventive Health Behaviors” (α= 0.81). Construct validity was confirmed for both the 25-item PRE-ADS-D and the “Acceptability of Screening” scale (α= 0.91). Overall, 51.2% of the participants showed a preference for screening. Non-parametric tests were conducted to further explore group differences of the sample. Conclusions: The PRE-ADS-D is a reliable and valid tool to measure attitudes, motives, and barriers regarding pre-symptomatic dementia screening in the German-speaking general population. Additionally, the subscale “Acceptability of Screening” demonstrated good construct validity and reliability, suggesting its promising potential as a practical tool in clinical practice.
Subject
Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience
Reference101 articles.
1. Alzheimer’s Disease International (2021) World Alzheimer Report 2021: Journey through the diagnosis of dementia . Alzheimer’s Disease International, London.
2. Fear about Alzheimer’s disease among Israeli and German laypersons, persons with Mild Neurocognitive Disorder and their relatives: A qualitative study;Werner;Int Psychogeriatr,2021
3. Rivastigmine for Alzheimer’s disease;Birks;Cochrane Database Syst Rev,2000
4. Lecanemab in early Alzheimer’s disease;van Dyck;N Engl J Med,2023
5. P4–173: The PRISM– PC questionnaire;Boustani;Alzheimers Dement,2006
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献